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1. Introduction 
1.1 AL amyloidosis 
Background 
Amyloidosis is a group of diseases characterized by the extracellular deposition of a 
proteinaceous material in various organs and tissues, leading to progressive multiple organ 
failure and death. The presence of cardiac involvement and its relative predominance varies 
with the type of amyloidosis, tends to progress rapidly and has a very poor prognosis. 
AL amyloidosis is the most common form of the disease. The heart in AL amyloidosis is 
affected in close to 50% of cases and amyloid deposition can be very rapidly progressive 
with increased untreated myocardial wall thickening at rates of up to 1.45–2.16 mm/month 
(Kristen et al., 2007). Heart failure (HF) is the presenting clinical manifestation in about half 
of these patients (Dubrey et al., 1998). Even among patients in whom another organ system 
dysfunction predominates, the presence of cardiac amyloidosis is frequently the worst 
prognostic factor (Kyle et al., 1995). Once HF occurs, the median survival is less then six 
months in untreated patients (Dubrey et al., 1998; Kyle et al., 1995). Although the overall 
survival of AL amyloidosis patients can be improved by the use of high dose chemotherapy 
and autologous stem-cell transplantation (ASCT) (Dey et al., 2010), the advanced cardiac 
disease at the time of diagnosis place these patients at a risk of 30% peri-treatment mortality 
(Falk et al., 1998). Marked wall thickening, elevated brain natriuretic peptide or elevated 
troponin predict poor outcomes and an ejection fraction < 40% is considered an absolute 
contraindication to high-dose chemotherapy and ASCT (Dispenzieri et al., 2003; Dispenzieri 
et al., 2004; Falk et al., 2005). However, it has been suggested that cardiac transplantation can 
restore health and permit subsequent administration of intensive chemotherapy. 
1.2 Cardiac transplantation for AL amyloidosis 
Cardiac transplantation for AL amyloidosis was first described in 1994 (Hall et al., 1994). 
Early experience came from individual case reports and small series, which demonstrated 
that short and medium term mortality, did not differ from that in other disorders (Dubrey et 
al., 2001; Hosenpud et al., 1991). However reports generated from a survey of heart 
transplantation (HTx) centers in the USA, Canada and Europe showed outcomes 
significantly inferior to those seen in cardiac transplantation for primary cardiomyopathy 
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(Hosenpud et al., 1990; Hosenpud et al., 1991). Survival at four years was 39% and systemic 
progression was seen in the majority of patients. The Heart Transplant Centers in the 
European consortium reported a five-year survival of 38% in recipients with AL amyloidosis 
compared with 67% in recipients with HF due to non-amyloid cases (Dubrey et al., 2004). 
Amyloid deposition occurred in the graft in every case in which it was sought histologically, 
and progressive systemic amyloidosis contributed to mortality in 70% of patients (Dubrey et 
al., 2001). United Network for Organ Sharing data (Kpodonu et al., 2005) are the largest 
published series of patients undergoing cardiac transplantation for AL amyloidosis which 
included 69 cardiac transplantations performed at 24 different centers in the USA, found a 
five-year survival of 54%. However, survival was not analyzed according to amyloid type in 
this study. Based on these discouraging outcomes amyloid heart disease has been 
considered a contraindication for HTx. Moreover, the need for adjunctive chemotherapy to 
suppress production of monoclonal light chains became obvious from the findings of several 
series that confirmed that relatively rapid development of cardiac allograft amyloid (Dubrey 
et al., 1995; Valantine et al., 1989;).  
In 2004, Skinner et al. reported a complete hematologic response, defined as no evidence of 
an underlying plasma cell dyscrasia one year after treatment, in 40% of patients with 
primary AL amyloidosis who received high-dose melphalan followed by autologous stem 
cell transplantation (Dey et al., 2010; Skinner et al., 2004). Recently cardiac transplantation 
followed by high-dose chemotherapy and ASCT has been shown to be feasible in carefully 
selected patients with AL amyloidosis and severe HF (Dey et al., 2010; Gillmore et al., 2006; 
Kristen et al., 2009; Lacy et al., 2008; Maurer et al., 2007; Mignot et al., 2008; Sattianayagam et  
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Reproduced from Dey et al., 2010 
Fig. 1. Kaplan-Meier disease free survival estimates, according to treatment MGH, 
orthotopic heart transplant followed by hematopoietic stem-cell transplant for cardiac 
amyloidosis; Hosenpud, orthotopic heart transplant alone for cardiac amyloidosis. 
Comparisons of survival between two groups of patients were made using the log-rank and 
Wilcoxon tests 
www.intechopen.com
 
Cardiac and Multi-Organ Transplantation in Patients with Amyloidosis 
 
173 
al., 2010). This treatment is aimed at preventing recurrence of amyloid in the cardiac 
allograft or progression of extra cardiac amyloidosis, thus long-term remission and apparent 
improvement in long term survival in carefully selected patients can been achieved. (Fig. 1) 
Gillmore et al., reported five patients with AL amyloidosis and predominant cardiomyopathy 
undergoing sequential HTx followed by ASCT: three patients survived for more than nine 
years without evidence of recurrence and two patients died of progressive amyloidosis at 33 
and 90 months after HTx (Gillmore et al., 2006). This study also showed that relapse of the 
plasma cell dyscrasia after ASCT was associated with characteristic echocardiographic 
evidence of cardiac amyloidosis and rise in serum NT-pro-BNP. Maurer et al., reported on 
10 patients who underwent HTx for AL amyloidosis (Maurer et al., 2007). In this study 
among eight patients who received subsequent ASCT, two died from sepsis and lymphoma. 
The median survival from cardiac transplantation of 9.7 years in this series is comparable to 
US all-cause cardiac transplant survival (Sattianayagam et al., 2010).  
The largest case scenarios came from Mayo Clinic and Massachusetts General Hospital (Dey 
et al., 2010; Lacy et al., 2008). In report of Dey et al., five of eight patients who underwent 
sequential HTx /ASCT were alive with a good functional status at a median follow-up of 56 
months (range, 7–101 months). None have evidence of recurrent amyloidosis, with four  
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Fig. 2. Kaplan-Meier overall survival estimates, according to treatment. Comparisons of 
survival between OHT and OHT+ASCT groups of patients (p=0.87, log-rank and Wilcoxon 
tests)  
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remaining in complete hematologic remission. The survival of these patients (Figure 2) was 
60% at seven years, which is not significantly different from the outcomes of 17,389 patients 
collected in the database of the International Society for Heart and Lung Transplantation 
who underwent HTx for non-amyloid heart disease during the same time. Lacy et al., from 
the Mayo Clinic have published a series of 11 carefully selected patients undergoing 
sequential HTx /ASCT. They reported a one and five-year survival of 82% and 65%, 
respectively (Lacy et al., 2008). Although two patients died from transplant-related toxicity 
and three patients died from progressive amyloidosis, the survival was comparable to 
patients undergoing HTx for non-amyloid disease. 
Thus, the data indicates that reasonable outcomes are achievable in patients with severe 
cardiac AL amyloidosis after HTx if underlying dyscrasia plasma cell is successfully treated 
afterward.  
1.3 Selection criteria 
In the early experience of cardiac transplantation for AL amyloidosis, patients were not 
screened to exclude extensive systemic involvement and a significant degree of systemic 
involvement may have accounted for the particularly poor prognosis. Careful patient 
selection may have contributed at least partially to improved outcomes in more recent 
studies.  
The baseline evaluation of all patients being considered for transplantation includes bone 
marrow aspirate and biopsy, echocardiogram, serum and 24-hour urine monoclonal protein 
studies, immunoglobulin-free light-chain assay, a chemistry panel including creatinine, liver 
function tests and renal clearance estimates (Gertz et al., 2005). 
In the Mayo Clinic series, selection criteria for cardiac transplantation included advanced 
cardiomyopathy, age under 60 years, and absence of myeloma or extensive extra-cardiac 
amyloidosis (Lacy et al., 2008). (Table 1) 
In the MGH data, however, in addition to advanced cardiac disease extra cardiac solid 
organ involvement by amyloidosis was present in all patients at the time of evaluation: all 
but one of the patients had evidence of amyloid deposition in the gastrointestinal tract, 
significant proteinuria was present in two and peripheral neuropathy in three HTx patients. 
Monoclonal plasma cells comprised 5% to 10% of marrow cellularity (Dey et al., 2010).  
1.4 Waiting period 
Unfortunately, patients with AL amyloidosis and severe HF have an extraordinarily poor 
prognosis on completing their cardiac transplant evaluation. Of 26 patients evaluated in the 
MGH series, 18 patients were selected and listed for HTx/ASCT, but only half survived to 
HTx (Dey et al., 2010). In the Mayo Clinic experience, of 54 patients evaluated, 27 patients 
were selected and listed for HTx but nine died while on the waiting list and six were 
removed from the list due to progressive disease. Only 11 patients (20%) underwent cardiac 
transplantation. In the study of Sattianayagam et al., less than 2% of all patients with 
systemic AL amyloidosis assessed at the United Kingdom National Amyloidosis Center 
underwent cardiac transplantation (Sattianayagam et al., 2010). 
Despite the significant risk of death associated with the use of vigorous chemotherapy in 
patients with AL cardiac amyloidosis, it should be considered in selected patients: a clinical 
improvement in HF despite an unchanged echocardiographic appearance has been reported 
(Dubrey et al., 1996). This improvement may result from the abolition of the production of 
freshly produced light chains, which have been shown to be toxic to myocardial cells,  
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Adapted from Lacy et al., 2008  
Table 1. Cardiac Transplantation: pre-transplant evaluation of AL amyloid patients 
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suggesting that AL amyloidosis is not simply an infiltrative cardiomyopathy but rather a 
toxic infiltrative disorder (Brenner et al., 2004; Falk et al., 2005; Liao et al., 2001; Nakamura et 
al., 2002). Despite the risk and delayed clinical benefits (Skinner et al., 1996), successful 
outcomes have been reported in small numbers of patients treated with chemotherapy 
followed by cardiac transplantation (Mignot et al., 2008). At the United Kingdom National 
Amyloidosis Center five patients were fit enough to receive chemotherapy and achieved a 
partial hematologic response before cardiac transplantation. Similarly, one patient at Mayo 
Clinic and two patients at MGH received systemic therapy consisting of melphalan and 
prednisone before cardiac transplantation. In cases when a substantial delay before the 
cardiac transplant is likely, the earlier application of plasma-cell-targeted therapeutic 
approaches with newer agents, such as bortezomib and lenalidomide (Kastritis et al., 2007; 
Sanchorawala et al., 2007) which are effective and better tolerated than conventional 
chemotherapeutic agents, beginning at the time of the evaluation process may be beneficial, 
and improve patients’ chances for receiving an HTx. A similar approach may also be 
considered for patients who are not ready for ASCT after cardiac transplantation since a 
prolonged time without treatment may allow progression of the amyloidosis and therefore 
both impair the candidacy of these patients for ASCT and increase their transplant related 
mortality (Dey et al., 2010; Lacy et al., 2008). 
1.5 Timing of ASCT after the HTx 
During the last several years, ASCT has undergone further refinement, including changes in 
supportive care and a better understanding of the complications of ASCT that are unique to 
amyloid patients. The optimal timing of ASCT after the HTx is debatable. Pursuing ASCT 
too soon may be problematic if the patient continues to require intensive immunosuppression 
to prevent organ rejection. Waiting too long may result in the amyloidosis progressing in 
other organs. Therefore, at the present time, it is recommended that ASCT be pursued 
approximately six to seven months after HTx (Dey et al., 2010; Lacy et al., 2008).  
1.6 Recurrence of cardiac amyloidosis 
Although in the United Kingdom study the patients were followed for two to six years with 
serial endomyocardial biopsies with no evidence of recurrent amyloid deposition during 
this time (Dubrey et al., 2004), five of the 11 patients reported by Lacy et al., demonstrated 
biopsy-proven recurrence in the cardiac allograft. Interestingly, none of these patients had 
symptoms, echocardiographic evidence, or biochemical evidence of cardiac amyloidosis. A 
similar observation was reported by Dey et al., demonstrating that amyloid deposition in 
their heart transplant patients has had little clinical consequence, with no echocardiographic 
evidence of amyloid cardiomyopathy. By contrast, Gilmore showed that relapse of the 
plasma cell dyscrasia after ASCT was associated with characteristic echocardiographic 
evidence of cardiac amyloidosis and rise in serum NT-pro-BNP. The varying results may be 
secondary to multiple factors, including the type of chemotherapy used, the timing of ASCT 
following heart transplant, the type of underlying plasma cell dyscrasia as well as 
individual patient factors (Luk et al., 2009). Nevertheless, the recurrent disease despite 
aggressive multimodality therapy is a reminder that it may be difficult to prevent recurrent 
protein deposition in patients with AL amyloidosis. Although conclusions are limited by the 
small sample size, it is likely that ASCT following cardiac transplantation results in a lack of 
clinically significant recurrent amyloidosis despite the presence of recurrent amyloid 
deposition and prolongs the interval of disease recurrence in the cardiac allograft. However, 
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it is possible that future survival of patients with disease recurrence in the cardiac allograft 
beyond the time described may be limited (Dey et al., 2010).  
1.7 Conclusions 
Although a multidisciplinary approach dedicated to early diagnosis, appropriate and timely 
screening for HTx and a multimodality plasma cell dyscrasia specific strategy may offer 
long-term remission for carefully selected patients with cardiac amyloidosis, HTx for amyloid 
cardiomyopathy continues to generate controversy because of the donor shortage and 
concerns about recurrence either in the transplanted heart or other vital organs. Clinical trials 
are still required to clarify which patients are most likely to achieve durable remissions after 
HTx and which chemotherapy strategy is most effective to eradicate the plasma cell clone. 
1.8 Combined heart and kidney transplantation in patients with AL amyloidosis 
AL amyloidosis is a multi-organ disease and the proportion of patients with cardiac AL 
amyloidosis and minimal systemic disease at the time of diagnosis is less than 5% (Dubrey et 
al., 1998). Cardiac amyloidosis frequently coexists with renal involvement which is 
characterized by nephrotic proteinuria and progressive worsening of renal function. 
However there are only two published cases of combined organ transplantation in patients 
with AL amyloidosis. Because of significant renal impairment, one patient received a 
combined heart and kidney transplantation (CHKTx) followed by ASCT at MGH and is 
reported to be alive up to 65 months with no evidence of recurrence. In case of partial 
hematologic remission induced by two courses of oral melphalan plus prednisone, followed 
by CHKTx, without ASCT, resulting in excellent renal and cardiac allograft function at three 
years has been reported (Audard et al., 2009). 
2. Familial amyloidosis (ATTR) 
2.1 Introduction 
Familial amyloidosis (ATTR) is a fatal autosomal-dominant multisystem disorder induced 
by deposition in several organs of abnormal serum ATTR (prealbumin) protein which is 
mainly produced in the liver. Amongst the over 40 mutations described, the Portuguese 
variant (ATTR Met30) is the most frequent and not associated with cardiomyopathy. 
Orthotopic liver transplantation is established as the treatment of choice for ATTR Met30 
with stabilization or remission of symptoms. In patients with a non-ATTR Met30 mutation 
and cardiomyopathy, after isolated liver transplantation (ILTx), the amyloid fibril deposition 
in the heart is increased suggesting that wild-type ATTR probably constitutes amyloid in the 
heart similar to the phenomenon observed in senile systemic amyloidosis (Stangou et al., 
1998; Westermark et al., 1990; Yazaki et al., 2000). This leads to progression of cardiomyopathy 
following ILTx in patients carrying a non-ATTR Met30 mutation and suggests that CHLTx is 
the procedure of choice (Pomfret et al., 1998). The first case of CHLTx in familial amyloidosis 
patients was reported by (Rela et al., 1995), however, the world-wide experience of this is 
small, and less than 25 cases of CHLTx have been reported in the medical literature.  
2.2 Survival after CHLTx in ATTR amyloidosis 
CHLTx experience has been analyzed for ATTR disease in the United Kingdom and the five-
year survival has been shown to be comparable with survival after transplantation for other 
diseases suggesting that this procedure should be indicated for several non-ATTR Met30 
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variants with recognized risk for progressive amyloid cardiomyopathy (Dubrey et al., 2004). 
A relatively large series from Mayo Clinic demonstrates the feasibility and excellent short 
and long term success that can be achieved with CHLTx for selected high-risk patients with 
familial amyloidosis. Indeed, patient survival after CHLTx was shown to be equivalent to 
those with IHTx. (Figure 3) 
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IHTx – isolated heart transplantation. CHLTx – combined heart and liver transplantation. 
Reproduced from Raichlin et al., 2009  
Fig. 3. Survival rates for FA patients at 1 month, 1 year, 5 and 10 years were 100%, 100%, 
75%, and 60% and did not differ from IHTx (97%, 93%, 83% and 65%, p=0.39, Log-Rank test) 
In the Mayo Clinic study, among 11 patients with ATTR the most frequent mutations were 
ALA 60 (4), and TYR 77 (3), followed by PRO 24 (1), SER (1) and ASP 18 GLU (1). One 
patient had an undefined mutation. This study showed that specific ATTR mutations do not 
affect the therapeutic success of CHLTx. Indeed, ALA 60 ATTR has been reported as a 
mutation of particularly poor prognosis and five of eight patients with ALA60 mutation 
described in the literature have died after ILTx (Kotani et al., 2002; Sharma et al., 2003). 
Moreover, the Tyr 77 ATTR (German variant) mutation is also typically associated with 
prominent and progressive cardiac involvement after ILTx (Garcia-Herola, 1999). In the 
Mayo Clinic report three of the four patients with ALA 60 ATTR mutation remain alive and 
one died of progressive renal failure; three patients with the TYR 77 ATTR variant remain 
alive and had no amyloid deposition on the last endomyocardial biopsy.  
Autonomic disturbances, modified body mass index, duration of symptoms, 
polyneuropathy, disability score, orthostatic hypotension, gastrointestinal and urinary tract 
dysfunction are important factors in the preoperative evaluation (Grazi et al., 2003; Sharma 
et al., 2003; Pilato et al., 2007) and optimizing the timing for CHLTx appears to be crucial.  
2.3 Surgical approaches for CHLTx 
Several different surgical approaches have been described for CHLTx: 
1. Transplantation of the heart but maintaining the patient on cardio-pulmonary bypass 
during the liver transplant was described. Subsequent concerns about substantial 
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coagulopathy and increased bleeding changed the strategy to performing liver 
implantation following separation from cardiopulmonary bypass (Befeler et al., 1999; 
Grazi et al., 2003; Shaw et al., 1985; Detry et al., 1997; Nardo et al., 2004). Improved surgical 
and anesthetic techniques during liver transplant, and the potential benefits to the 
transplanted heart to remain on cardio-pulmonary bypass during liver implantation led 
to revising this strategy for CHLTx. In the case study by Hennessey and colleagues, this 
technique was suggested to provide a considerably shortened liver ischemia time and 
decreased blood transfusion compared to the sequential approach (Hennessey et al., 2010).  
2. Transplantation of the heart with discontinuation of cardio-pulmonary bypass, leaving 
the chest opened. The liver transplantation was performed as a second step through a 
bilateral sub-costal incision with extension in the midline to the sternotomy (Couetil et 
al., 1995) and was accomplished by a caval sparing hepatectomy with an anastomosis 
between the donor supra-hepatic cava and the recipient left/middle hepatic vein trunk. 
Biliary tubes were inserted through the donor cystic duct stumps whenever possible, 
and the abdomen was closed over drains after achieving hemostasis. (Raichlin et al., 
2009) One of the major advantages of this procedure is that CHLTx can be performed 
with minimal deviation from the standard procedures of IHTx and ILTx. 
3. Staged heart and liver transplantation was first reported by Figuera (Figuera et al., 1986) 
for patients who underwent HTx and were hemodynamically unstable after cardiac 
reperfusion. Subsequent liver transplantation was deferred, and the patients underwent 
deceased donor liver transplantation from a second donor.(Barreiros et al., 2010; Pilato 
et al., 2007)  
In the Mayo Clinic study simultaneous CHLTx was feasible in 87% (13 of 15) of patients and 
appears favorable if cardiac function and hemodynamics are satisfactory (Raichlin et al., 
2009). 
Based on the experience of several centers (Befeler et al., 1999; Raichlin et al., 2007a) it seems 
that renal failure secondary to hypo-perfusion from cardiopulmonary and veno-venous 
bypass, blood loss and the nephrotoxic effects of peri-operative medications (including 
inotropic agents and immunosuppressive drugs) complicate the early post-operative course 
of many patients following CHLTx. As demonstrated in the study from Mayo Clinic, none 
of the preoperative evaluations were able to predict such postoperative complications. 
Within one month following transplantation renal function improved in the CHLTx patients 
and was comparable with the isolated heart transplantation (IHTx) group. However, three 
patients (30%) developed late end-stage renal failure presumably as a result of calcineurin 
inhibitor toxicity (clinical picture was not consistent with amyloid glomerulopathy) and 
required hemodialysis. Therefore, renal function was significantly worse in the CHLTx 
patients at the late follow-up. It was previously demonstrated that the risk of chronic renal 
failure after transplantation of a non-renal organ depends on the type of organ transplanted 
and at five years the cumulative incidence of chronic renal failure was lower after IHTx 
(10.9±0.2) compared to ILTx (18.1±0.20) (Gonwa et al., 2001; Ojo et al., 2003). Calcineurin 
inhibitor sparing (Sirolimus based) immunosuppression probably should be considered in 
CHLTx patients to prevent progressive calcineurin inhibitor - induced renal damage 
(Raichlin et al., 2007a; Raichlin et al., 2007b). 
2.4 Acute cellular rejection 
Acute cellular rejection of the liver is infrequent in CHLTx (Raichlin et al., 2009). The more 
aggressive immunosuppression regimen employed for CHLTx compared with that used for 
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ILTx may make rejection of liver allografts a relatively infrequent event. Interestingly, heart 
rejection was less frequent in CHLTx than in those receiving IHTx. (Figure 4) To explain the 
favorable low rejection rate an induction of partial tolerance has been proposed as a 
mechanism. The liver has been demonstrated to permit acceptance of other simultaneously 
transplanted organs operating via shedding soluble HLA antigens (Davies et al., 1989; 
McMillan et al., 1997). It has been hypothesized that maintaining a concentration of soluble 
HLA in the circulation would lead to tolerance to the allotype of the soluble HLA. This 
concept may help explain the protection of a simultaneous heart transplant by a successful 
human liver transplant (Vogel et al., 1988). Therefore, less intensive immunosuppression 
therapy for these patients after CHLTx than for IHTx may be justified. 
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IHTx – isolated heart transplantation. CHLTx – combined heart and liver transplantation. 
Reproduced from Raichlin et al., 2009  
Fig. 4. Freedom from cardiac allograft rejection (International Society for Heart and Lung 
Transplantation ≥ Grade 2) for at 1 month was 83% and did not change further. For IHTx 
freedom from rejection at 1 month, 1 year, 3 years and 10 years was 80%, 48%, 42% and 32% 
respectively (p=0.02, Log-Rank test) 
2.5 Postoperative course and complications 
In the Mayo Clinic report for recipients of CHLTx the mean intensive care unit stay did not 
differ (p=0.23) and the mean hospital stay was not significantly longer than for IHTx 
(p=0.09).  
2.6 Pulmonary embolism  
Pulmonary embolism is a rare complication in early period post IHTx (Berroeta et al., 2006). 
In Mayo Clinic study two patients developed pulmonary embolism and were treated with 
anticoagulation. This high incidence of pulmonary embolism in recipients of CHLTx 
probably reflects the prolonged immobilization period and delayed recovery of 
anticoagulant proteins in this group of patients (Stahl et al., 1990).  
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2.7 Cardiac allograft function  
In the Mayo Clinic study, during a mean 65 month follow up, all heart allografts displayed 
normal systolic function on echocardiography with mean left ventricular ejection fraction 
65% ± 7% and no signs of left ventricular heart. Congo red stain and/or sulfated alcian blue 
stain was negative for amyloid in all patients. There has been no significant cardiac allograft 
vasculopathy in any of these. 
2.8 Use of amyloidotic livers for domino liver transplantation 
Since livers explanted from patients with FA contain only microscopic amyloid deposits and 
are otherwise essentially normal, and it typically takes approximately 50 years for TTR 
deposition to progress to clinically apparent disease, the FA liver can be used as a domino 
donor liver for selected older patients awaiting liver transplantation. CHLTx does not 
preclude domino donation of FA recipients’ liver. In contrast to caval sparing hepatectomy 
with an anastomosis between the donor supra-hepatic cava and the recipient left/middle 
hepatic vein trunk caval excision with veno-venous and portal-venous bypass was 
employed for FA patients serving as domino liver donors. None of the domino donors 
experienced any technical problems related to donation or veno-venous and porto-venous 
bypass. (Azoulay et al., 1999; Raichlin et al., 2009) 
3. Conclusion 
CHLTx for ATTR is a successful therapy for this disease and can be performed safely, with a 
acceptable level of morbidity. Given the 10-year survival of 60% with an associated freedom 
of rejection of 83%, the procedure is consistently curative in patients with ATTR and cardiac 
involvement. Specific ATTR mutations do not affect outcome. Cardiac allograft rejection 
after CHLTx is significantly less frequent than with IHTx and may justify less intensive 
immunosuppression therapy for these patients. In addition calcineurin sparing (sirolimus 
based) immunosuppression to prevent progressive calcineurin-induced renal damage 
should be considered in CHLTx recipients. 
4. References 
Audard V, Matignon M, Weiss L, et al. Successful long-term outcome of the first combined 
heart and kidney transplant in a patient with systemic Al amyloidosis. Am J 
Transplant. 2009;9:236-40  
Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: 
experience with familial amyloidotic polyneuropathy. J Am Coll Surg. 1999;189:584-
93 
Barreiros AP, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-
heart transplantation in patients with familial amyloid polyneuropathy: a single-
center experience. Liver Transpl, 2010; 16:314-23 
Befeler AS, Schiano TD, Lissoos TW, et al. Successful combined liver-heart transplantation in 
adults: report of three patients and review of the literature. Transplantation. 
1999;68:1423-7 
Berroeta C, Flament F, Lathyris D, et al. Pulmonary embolism: an uncommon cause of 
dyspnea after heart transplantation. J Cardiothorac Vasc Anesth. 2006;20:236-8. Epub 
2005 Dec 1 
www.intechopen.com
 
Amyloidosis – An Insight to Disease of Systems and Novel Therapies 
 
182 
Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair 
cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 
2004;94:1008-10. Epub 2004 Mar 25 
Couetil JP, Houssin DP, Soubrane O, et al. Combined lung and liver transplantation in 
patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg. 
1995;110:1415-22; discussion 1422-3 
Davies HS, Pollard SG, Calne RY. Soluble HLA antigens in the circulation of liver graft 
recipients. Transplantation 1989;47:524-7 
Detry O, Honore P, Meurisse M, et al. Advantages of inferior vena caval flow preservation in 
combined transplantation of the liver and heart. Transpl Int. 1997;10:150-1 
Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive 
melphalan and autologous stem-cell transplantation for light chain amyloidosis 
and heart failure. Transplantation 2010 Oct 27;90(8):905-11 
Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic 
amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-9 
Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain 
natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 
2004;22:3751-7 
Dubrey S, Simms RW, Skinner M, Falk RH. Recurrence of primary (AL) amyloidosis in a 
transplanted heart with four-year survival. Am J Cardiol. 1995;76:739-41 
Dubrey S, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL 
amyloidosis. Ann Intern Med. 1996;125:481-4 
Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain 
(AL) amyloidosis with heart involvement. Qjm. 1998;91:141-57 
Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR. Long term 
results of heart transplantation in patients with amyloid heart disease. Heart. 
2001;85:202-7 
Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid 
heart disease: the United Kingdom experience. J Heart Lung Transplant. 
2004;23:1142-53 
Falk RH RJ, Dubrey SW, Mendes LA, Sanchorawala V, Ekery, D CR, Vosburgh E, Skinner 
M. . The effect of cardiac involvement on the outcome of intravenous melphalan 
therapy and autologous stem cell rescue for AL amyloidosis. In: Kyle RA GM, eds., 
ed. Amyloid and the Amyloidoses: VIIIIth International Symposiumon Amyloidosis. 
Rochester, MN: Parthenon 1998:181–183 
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047-
60. 
Figuera D, Ardaiz J, Martin-Judez V, et al. Combined transplantation of heart and liver from 
two different donors in a patient with familial type IIa hypercholesterolemia. J 
Heart Transplant. 1986;5:327-9 
Garcia-Herola A, Prieto M, Pascual S, et al. Progression of cardiomyopathy and neuropathy 
after liver transplantation in a patient with familial amyloidotic polyneuropathy 
caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999;5:246-8 
Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment 
response in immunoglobulin light chain amyloidosis (AL): a consensus opinion 
from the 10th International Symposium on Amyloid and Amyloidosis, Tours, 
France, 18-22 April 2004. Am J Hematol. 2005;79:319-28 
www.intechopen.com
 
Cardiac and Multi-Organ Transplantation in Patients with Amyloidosis 
 
183 
Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell 
transplantation for systemic AL amyloidosis. Blood. 2006;107:1227-9. Epub 2005 Oct 6 
Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver 
transplantation (OLTX) using calcineurin-based immunotherapy: risk of 
development and treatment. Transplantation 2001;72:1934-9 
Grazi GL, Cescon M, Salvi F, et al. Combined heart and liver transplantation for familial 
amyloidotic neuropathy: considerations from the hepatic point of view. Liver 
Transpl. 2003;9:986-92 
Hall R, Hawkins PN. Cardiac transplantation for AL amyloidosis. Bmj. 1994;309:1135-7 
Hennessey T, Backman SB, Cecere R, et al. Combined heart and liver transplantation on 
cardiopulmonary bypass: report of four cases. 2010; Can;57:355-60  
Hosenpud JD, Uretsky BF, Griffith BP, O'Connell JB, Olivari MT, Valantine HA. Successful 
intermediate-term outcome for patients with cardiac amyloidosis undergoing heart 
transplantation: results of a multicenter survey. J Heart Transplant. 1990;9:346-50 
Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced 
long-term survival in patients with cardiac amyloidosis undergoing heart 
transplantation. Follow-up results of a multicenter survey. Circulation. 
1991;84:III338-43 
Kotani N, Hattori T, Yamagata S, et al. Transthyretin Thr60Ala Appalachian-type mutation 
in a Japanese family with familial amyloidotic polyneuropathy. Amyloid 2002;9:31-4 
Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients 
with amyloid cardiomyopathy. J Heart Lung Transplant. 2005;24:1763-5 
Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as 
a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J 
Heart Fail. 2009;11:1014-20 
Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 
cases. Semin Hematol. 1995;32:45-59 
Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac 
amyloidosis. Eur J Heart Fail. 2007;9:617-24 
Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart 
transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 
2008;27:823-9 
Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis 
causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104:1594-7 
Luk A, Ahn E, Lee A, Ross HJ, Butany J. Recurrent cardiac amyloidosis following previous 
heart transplantation. Cardiovasc Pathol 2009;19:9 
Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor 
criteria organs for systemic amyloidosis complicated by heart failure. 
Transplantation. 2007;83:539-45 
McMillan RW, Gelder FB, Zibari GB, Aultman DF, Adamashvili I, McDonald JC. Soluble 
fraction of class I human histocompatibility leukocyte antigens in the serum of liver 
transplant recipients. Clin Transplant 1997;11:98-103 
Mignot A, Bridoux F, Thierry A, et al. Successful heart transplantation following melphalan 
plus dexamethasone therapy in systemic AL amyloidosis. Haematologica. 
2008;93:e32-5 
Nakamura M, Satoh M, Kowada S, et al. Reversible restrictive cardiomyopathy due to light-
chain deposition disease. Mayo Clin Proc. 2002;77:193-6 
www.intechopen.com
 
Amyloidosis – An Insight to Disease of Systems and Novel Therapies 
 
184 
Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four 
adults with familial amyloidosis: experience of a single center. Transplant Proc 
2004;36:645-7 
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal 
organ. N Engl J Med 2003;349:931-40 
Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for 
familial amyloidotic neuropathy. Eur J Cardiothorac Surg. 2007;32:180-2Raichlin E, 
Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus 
as primary immunosuppression in stable cardiac transplant recipients. 
Transplantation. 2007;84:467-74 
Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary 
immunosuppression attenuates the progression of allograft vasculopathy after 
cardiac transplantation. Circulation. 2007;116:2726-33 
 Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-
center experience. Transplantation 2009;88:219-25 
Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of 
patients with AL amyloidosis treated with high-dose melphalan and stem-cell 
transplantation. Blood 2007;110:3561-3 
 Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ transplantation in AL 
amyloidosis Outcomes of heart transplantation for cardiac amyloidosis: subanalysis 
of the Spanish registry for heart transplantation. Am J Transplatn. 2010;10(9):2124-31 
Sharma P, Perri RE, Sirven JE, et al. Outcome of liver transplantation for familial amyloidotic 
polyneuropathy. Liver Transpl 2003;9:1273-80 
Shaw BW, Jr., Bahnson HT, Hardesty RL, Griffith BP, Starzl TE. Combined transplantation 
of the heart and liver. Ann Surg 1985;202:667-72 
Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: 
a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. 
Am J Med. 1996;100:290-8 
Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell 
transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 
2004;140:85-93 
Stahl RL, Duncan A, Hooks MA, Henderson JM, Millikan WJ, Warren WD. A 
hypercoagulable state follows orthotopic liver transplantation. Hepatology 
1990;12:553-8 
Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver 
transplantation for familial amyloid polyneuropathy: implications for amyloid 
fibrillogenesis. Transplantation 1998;66:229-33 
Valantine HA, Billingham ME. Recurrence of amyloid in a cardiac allograft four months 
after transplantation. J Heart Transplant. 1989;8:337-41 
Vogel W, Steiner E, Kornberger R, et al. Preliminary results with combined hepatorenal 
allografting. Transplantation 1988;45:491-3 
Westermark P, Sletten K, Johansson B, Cornwell GG, 3rd. Fibril in senile systemic 
amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 
1990;87:2843-5 
Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid 
polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys 
Res Commun 2000;274:702-6 
www.intechopen.com
Amyloidosis - An Insight to Disease of Systems and Novel
Therapies
Edited by Dr. Işıl Adadan Güvenç
ISBN 978-953-307-795-6
Hard cover, 194 pages
Publisher InTech
Published online 16, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Amyloidosis is a benign, slowly progressive condition characterized by the presence of extracellular fibrillar
proteins in various organs and tissues. It has systemic or localized forms. Both systemic and localized
amyloidosis have been a point of interest for many researchers and there have been a growing number of
case reports in the literature for the last decade. The aim of this book is to help the reader become familiar
with the presentation, diagnosis and treatment modalities of systemic and localized amyloidosis of specific
organs or systems and also cover the latest advancements in therapy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Eugenia Raichlin and Sudhir S. Kushwaha (2011). Cardiac and Multi-Organ Transplantation in Patients with
Amyloidosis, Amyloidosis - An Insight to Disease of Systems and Novel Therapies, Dr. Işıl Adadan Güvenç
(Ed.), ISBN: 978-953-307-795-6, InTech, Available from: http://www.intechopen.com/books/amyloidosis-an-
insight-to-disease-of-systems-and-novel-therapies/cardiac-and-multi-organ-transplantation-in-patients-with-
amyloidosis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
